폐쇄성 세기관지염 증후군 시장 규모, 점유율 및 성장 분석 : 치료 클래스별, 환자 개요별, 진단 및 모니터링별, 최종사용자별, 지역별 - 업계 예측(2026-2033년)

Global Bronchiolitis Obliterans Syndrome Market size was valued at USD 2.0 Billion in 2024 and is poised to grow from USD 2.18 Billion in 2025 to USD 4.34 Billion by 2033, growing at a CAGR of 9.0% during the forecast period (2026-2033).

The bronchiolitis obliterans syndrome market is witnessing robust growth, driven primarily by an increasing population of transplant survivors who experience chronic airway fibrosis. This condition often follows lung and hematopoietic stem cell transplants, necessitating ongoing diagnostics and therapeutics due to its potential to progress into respiratory failure if left untreated. Advancements in perioperative care have led to higher survival rates, revealing management gaps that previously relied on limited therapies. Current market dynamics reflect a shift toward integrated diagnostics, including routine surveillance spirometry and biomarker assessments, allowing earlier interventions. Additionally, AI technologies are enhancing diagnostic accuracy by identifying subtle imaging patterns and predicting conditions like rejection, fostering investment and development in novel therapeutics and monitoring solutions that cater to this underserved market.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Bronchiolitis Obliterans Syndrome market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Bronchiolitis Obliterans Syndrome Market Segments Analysis

Global bronchiolitis obliterans syndrome market is segmented by therapeutic class, patient profile, diagnosis & monitoring, end-user and region. Based on therapeutic class, the market is segmented into Immunosuppressants, Inhaled Corticosteroids, Antifibrotic Agents and Specialized Inhaled Cyclosporine. Based on patient profile, the market is segmented into Post-Lung Transplant Recipients and Allogeneic Hematopoietic Stem Cell Transplant (HSCT). Based on diagnosis & monitoring, the market is segmented into Spirometry and High-resolution CT (HRCT) Imaging. Based on end-user, the market is segmented into Transplant Centers, Pulmonology Specialty Hospitals and Clinical Research Organizations. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Bronchiolitis Obliterans Syndrome Market

The increasing prevalence of bronchiolitis, along with associated chronic airway obstruction, is driving demand for effective diagnostic, therapeutic, and supportive interventions in the Bronchiolitis Obliterans Syndrome market. This escalating need compels healthcare providers and manufacturers to broaden their product offerings and invest in clinical research and development. As clinicians see more cases with severe or persistent symptoms, there is a shift towards adopting advanced diagnostic methodologies and treatment protocols, which in turn fuels the creation of specialized medications, medical devices, and comprehensive care pathways. This heightened clinical requirement fosters new market entrants and strategic collaborations aimed at bridging therapeutic gaps and enhancing patient outcomes.

Restraints in the Global Bronchiolitis Obliterans Syndrome Market

The Global Bronchiolitis Obliterans Syndrome market faces significant restraints stemming from the slow adoption of innovative therapies and a strong dependence on traditional supportive care methods. This situation restricts market growth as it hampers the rate of prescription adoption and stifles commercial progress. Healthcare providers may be reluctant to alter established treatment protocols without compelling long-term evidence of positive outcomes, while institutional formularies and clinical guidelines often necessitate a gradual approach to incorporating new therapies. Such caution leads to diminished returns on investment in development, discouraging manufacturers from expanding production or aggressively entering the market, ultimately hindering access to improved treatment alternatives.

Market Trends of the Global Bronchiolitis Obliterans Syndrome Market

The Global Bronchiolitis Obliterans Syndrome market is witnessing a significant trend towards personalized therapy development, emphasizing individualized treatment approaches that cater to the diverse immune profiles and disease phenotypes of patients. Innovations in molecular profiling and translational research are paving the way for targeted immunomodulatory therapies, enhancing the overall efficacy of care. This shift promotes collaborative efforts among clinicians and researchers to integrate diagnostic insights, ensuring that therapeutic selections are closely aligned with patient-specific clinical needs. Consequently, the market is experiencing heightened activity focused on platforms supporting the implementation of precision medicine, ultimately enhancing partnerships and differentiating product offerings.

Table of Contents

Introduction

• Objectives of the Study
• Market Definition & Scope

Research Methodology

• Research Process
• Secondary & Primary Data Methods
• Market Size Estimation Methods

Executive Summary

• Global Market Outlook
• Key Market Highlights
• Segmental Overview
• Competition Overview

Market Dynamics & Outlook

• Macro-Economic Indicators
• Drivers & Opportunities
• Restraints & Challenges
• Supply Side Trends
• Demand Side Trends
• Porters Analysis & Impact
  • Competitive Rivalry
  • Threat of Substitute
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factors
• Market Impacting Factors
• Top Investment Pockets
• Ecosystem Mapping
• Market Attractiveness Index 2025
• PESTEL Analysis
• Regulatory Landscape

Global Bronchiolitis Obliterans Syndrome Market Size by Therapeutic Class & CAGR (2026-2033)

• Market Overview
• Immunosuppressants
• Inhaled Corticosteroids
• Antifibrotic Agents
• Specialized Inhaled Cyclosporine

Global Bronchiolitis Obliterans Syndrome Market Size by Patient Profile & CAGR (2026-2033)

• Market Overview
• Post-Lung Transplant Recipients
• Allogeneic Hematopoietic Stem Cell Transplant (HSCT)

Global Bronchiolitis Obliterans Syndrome Market Size by Diagnosis & Monitoring & CAGR (2026-2033)

• Market Overview
• Spirometry
• High-resolution CT (HRCT) Imaging

Global Bronchiolitis Obliterans Syndrome Market Size by End-User & CAGR (2026-2033)

• Market Overview
• Transplant Centers
• Pulmonology Specialty Hospitals
• Clinical Research Organizations

Global Bronchiolitis Obliterans Syndrome Market Size & CAGR (2026-2033)

• North America (Therapeutic Class, Patient Profile, Diagnosis & Monitoring, End-User)
  • US
  • Canada
• Europe (Therapeutic Class, Patient Profile, Diagnosis & Monitoring, End-User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Therapeutic Class, Patient Profile, Diagnosis & Monitoring, End-User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Therapeutic Class, Patient Profile, Diagnosis & Monitoring, End-User)
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Therapeutic Class, Patient Profile, Diagnosis & Monitoring, End-User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Novartis AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Roche
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline (GSK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol-Myers Squibb
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharma
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amgen Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceuticals
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cipla Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sun Pharma
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Lupin Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Chiesi Farmaceutici
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Vertex Pharmaceuticals
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• United Therapeutics
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Insmed Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Viatris
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations